The Food and Drug Administration granted Fast Track designation to
MedicNova Inc.’s (Nasdaq: MNOV) MN-001 to treat nonalcoholic steatohepatitis
with fibrosis. The stock price leaped $1.45 to close at $4.96.
FDA grants fast track status to MedicNova
April 16, 2015 at 11:33 AM EDT
